Introduction
============

Prostate cancer is the most common cancer among men, accounting for 20.7% of the projected 103,100 cancer diagnoses in Canadian men in 2017.[@b1-rru-11-069] About one in six men in North America will be diagnosed with prostate cancer in their lifetime, and 80% of men over the age of 80 years have at least microfocal disease.[@b2-rru-11-069] Despite its high incidence, the lifetime risk of dying of prostate cancer in North America remains low, at only 2.5%.[@b2-rru-11-069] This discrepancy is due to the fact that low-risk prostate cancer accounts for \>50% of new diagnoses.[@b2-rru-11-069] Prostate cancer is often a relatively indolent disease associated with slow progression, and many affected individuals ultimately die with the disease and not of it.[@b3-rru-11-069] Standard interventions for prostate cancer, including radical prostatectomy (RP) and radiotherapy, are associated with significant adverse effects on the sexual, urinary, and bowel function of the patient.[@b2-rru-11-069]

Over the last 15 years, there has been a widespread shift toward more conservative management of low-risk prostate cancer. One of the foundations of this new paradigm is the concept of active surveillance (AS), in which treatment is deferred in men with low-risk prostate cancer diagnoses until there is evidence of disease progression. Though there are no standardized and uniformly accepted surveillance protocols, monitoring consists of serial prostate-specific antigen (PSA) tests, digital rectal exams, and prostate biopsies.

Numerous prospective randomized trials have been undertaken comparing outcomes of observation or AS vs curative treatment in patients with localized prostate cancer. PIVOT randomized men with localized prostate cancer to either RP or watchful waiting.[@b4-rru-11-069] This study found no significant difference in all-cause or prostate-specific mortality between the two arms, especially in men with low-risk disease, and the recently published update with additional follow-up maintained these findings.[@b4-rru-11-069],[@b5-rru-11-069] The PROTECT trial compared AS to RP and radiotherapy in men with clinically localized prostate cancer. Similarly to PIVOT, no significant difference was observed in all-cause or prostate-specific mortality among the three groups.[@b6-rru-11-069] The results of both these prospective randomized trials indicated that men with low-risk prostate cancer can safely avoid the risks of early radical intervention.

Given the growing body of evidence supporting the safety of conservative management for low-risk prostate cancer, its adoption has increased significantly in North America over the past decade and a half. Studies examining large patient cohorts within the National Cancer Database (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) database have found significant increases in the proportion of low-risk and very low-risk prostate cancer patients undergoing noncurative initial management, as opposed to curative intervention.[@b7-rru-11-069],[@b8-rru-11-069]

The PSA era has led to overdiagnosis of prostate cancer, due to the widespread use of prostate needle-core biopsies, which increased detection of "insignificant prostate cancer" representing low-volume/low-grade disease.[@b9-rru-11-069] A disease that would have previously gone undiagnosed has become increasingly recognized and treated, often at the expense of patients' health and quality of life. Therefore, AS has become a clinical necessity and well-accepted and widely utilized management option aimed at mitigating the overtreatment of low-risk prostate cancer. Indeed, Cancer Care Ontario guidelines considered AS the recommended disease-management strategy for most patients with low-risk disease.[@b10-rru-11-069] More recently, a 2018 European Association of Urology position article stated that AS should be considered for all men with low-risk prostate cancer who are fit for curative treatment and willing to adhere to the protocol.[@b11-rru-11-069] We undertook an institutional retrospective study to assess RP trends over the past decade, evaluate our institutional risk-group stratification, and in particular the proportion of low-risk prostate cancer patients who underwent RP during the study period.

Methods
=======

Full ethics approval was obtained from the Conjoint Health Research Ethics Board at the University of Calgary. Given that this study was retrospective in nature using deidentified patient information, patient consent for review of medical records was not required. Maintenance of patient-data confidentiality was in accordance with the Declaration of Helsinki. We retrospectively reviewed all patients who underwent RP from February 2005 to October 2014 at our institution. The first major revision of the Gleason grading system for prostatic carcinoma occurred in 2005 at an International Society of Urological Pathology Gleason consensus conference. We used the last transrectal ultrasound--guided biopsy (TRUS-bx) prior to surgical intervention for the analysis. TRUS-bx was performed using a standardized template, which typically included 12 cores sampled from the apex, mid, and base, bilaterally. RPs were also completely sampled. Both TRUS-bx and RPs were analyzed in a centralized genitourinary pathology setting and reported using standardized protocols. Patients were stratified according to TRUS-bx D'Amico risk classifications: low risk, clinical T1c-T2a and PSA \<10 and Gleason score 6; intermediate risk, clinical T2b or PSA 10--20 or Gleason score 7; high risk, clinical ≥T2c or PSA ≥20 or Gleason score 8--10. We report the annual number of RPs performed at our institution stratified by TRUS-bx D'Amico risk classification from 2005 to 2014, as well as by grade group. RP findings are reported from February 2005 to October 2014 to describe concordance between TRUS-bx and RP. Basic descriptive analysis was used for this study.

Results
=======

[Table 1](#t1-rru-11-069){ref-type="table"} shows the number of RPs performed between 2005 and 2014, stratified by risk category at biopsy. Over the 10-year period, 35.2% of all RPs were performed on men with low-risk prostate cancer. However, there was a downward trend, with procedures for low-risk prostate cancer decreasing from 54.0% of all RPs in 2005 to 8.9% in 2014, as shown in [Table 1](#t1-rru-11-069){ref-type="table"} and [Figure 1](#f1-rru-11-069){ref-type="fig"}.

There was a corresponding upward trend in the proportion of procedures performed on intermediate-risk patients, increasing from 42.0% of the total in 2005 to 75.6% in 2014 ([Figure 1](#f1-rru-11-069){ref-type="fig"}). High-risk patients also accounted for an increased proportion of RPs, up from 4.0% in 2005 to 15.6% in 2014 ([Figure 1](#f1-rru-11-069){ref-type="fig"}). [Figure 2](#f2-rru-11-069){ref-type="fig"} demonstrates the pathological grade-group migration that has taken place over the 10-year period. Grade group 1 on biopsy accounted for 60.8% of RPs in 2005 compared to 10.0% in 2014. Conversely, clinically significant prostate cancer (≥ grade group 2) on biopsy increased from 39.2% to 90.0% of RPs.

[Table 2](#t2-rru-11-069){ref-type="table"} shows pathological findings on RP, stratified by risk category at biopsy. Of note, although 405 (49.8%) patients who underwent RP for low-risk prostate cancer had upgrading of their disease on final pathology, 374 (46.0%) of these were upgraded to favorable intermediate (grade group 2), with only 3.8% upgraded to grade group 3 or greater. Overall, in the low-risk patient group, 7.6% of patients were stage pT3 (6.6% pT3a and 1.0% pT3b). Of the 543 low-risk RP patients in whom lymph nodes were assessed, only two (0.4%) had nodal disease. Lymphovascular invasion was present in 1.8% of the low-risk group.

Discussion
==========

We found a clear downward trend in the proportion of RPs performed on men with low-risk prostate in our center (54% in 2005 compared to 8.9% in 2014). This is similar to the overall trends observed in North America and Europe, which show decreasing rates of curative intervention for men with low-risk prostate cancer. One European multicenter study found that the percentage of patients who had undergone RP and were subsequently found to have localized Gleason 6 disease decreased from 46% in 2000 to 8% in 2015.[@b12-rru-11-069] Similarly, a recent study comparing RP trends at Copenhagen University Hospital and Stanford University Hospital found that the proportion of RPs performed on low-risk prostate cancer patients decreased between 2000 and 2013 in both institutions (26.5%--16.6% in Denmark and 41.5%--27.9% at Stanford).[@b13-rru-11-069] Finally, a recent large study involving over 125,000 Veterans' Affairs patients with low-risk prostate cancer in the US found that radical management in men \>65 years of age decreased from 65% to 21% between 2005 and 2015.[@b14-rru-11-069]

The decreasing rates of definitive intervention for men with low-risk prostate cancer has been offset by the widespread adoption of AS. An analysis of very low-risk prostate cancer patients in the NCDB found that among patients eligible for AS, the percentage of those enrolled in AS increased from 11.6% in 2010 to 27.3% in 2013.[@b8-rru-11-069] Another study looking at both the SEER database and the NCDB found that noncurative initial management (watchful waiting or AS) rose from 21% to 32% in SEER and 13% to 20% in NCDB for patients with low-risk prostate cancer.[@b7-rru-11-069] Finally, the Veterans' Affairs study previously mentioned largely attributed the decrease in radical treatment for low-risk prostate cancer to significant uptake of AS, with AS rates increasing from 3% to 41% in men aged \>65 years from 2005 to 2015 and from 4% to 39% in men \<65 years of age.[@b14-rru-11-069]

It is however evident that although AS rates have been increasing, this still represents an underutilized tool in the management of low-risk prostate cancer.[@b15-rru-11-069] The Veterans' Affairs study highlighted that AS rates in Europe remain considerably higher than in the US: as high as 74% in Sweden in 2014.[@b14-rru-11-069] Because our data were limited to patients who had undergone RP and did not include other management options, we cannot directly comment on our institutional rate of AS. However, the observed downward trend of the proportion of RPs performed in low-risk patients in our institution follows the global trend of noncurative management for patients with low-risk disease. The fact that that almost 10% of all RPs performed at our institution were done in patients with low-risk disease at the conclusion of the study period may also indicate that there is still room to increase further the number of patients managed by AS. This is further supported by the fact that \>50% of the low-risk patients who underwent RP were not upgraded on subsequent pathology of the RP specimen. Furthermore, adverse findings on final pathology, namely pT3 disease, positive node status, and lymphovascular invasion, were uniformly low in the low-risk group. Many of these patients would thus have likely been good candidates for AS.

There are a number of potential barriers that may potentially inhibit further increases of watchful waiting or AS for low-risk prostate cancer and maintain the persistence of definitive treatment of this generally indolent type of disease. The main obstacle is certainly the risk of disease progression that is expected in situations of conservative cancer management. The extended follow-up of PIVOT found that disease progression was more common among men assigned to observation than those assigned to surgery.[@b5-rru-11-069] Disease progression of all types occurred in 68.4% of observation patients vs 40.9% of surgery patients. Patients under observation also had a 4.5% higher absolute risk of metastasis than surgery patients.[@b5-rru-11-069] Moreover, this disparity is likely underrepresenta-tive of the true difference, because of the significant crossover between the study arms: 21% of patients in the surgery arm had never had an RP, and 20% of patients in the observation group ultimately received definitive treatment.[@b5-rru-11-069] AS was also shown to be associated with higher rates of disease progression in the PROTECT trial, which showed that the incidence of overall clinical progression and metastatic disease was significantly higher in the AS group (22.9 vs 8.9 per 1,000 person-years for overall clinical progression, and 6.3 vs 2.4 per 1,000 person-years for metastatic disease).[@b6-rru-11-069] Therefore, interventions for low-risk prostate cancer, whether by RP or radiotherapy, are inevitably associated with lower rates of disease progression. Nonetheless, the higher disease-progression rates seen with conservative management in both the PIVOT and PROTECT trials did not translate into higher mortality. In PROTECT, there was no significant difference in prostate cancer--specific mortality among the AS, RP, and radiotherapy groups (10-year survival of 98.8%, 99.0%, and 99.6%, respectively).[@b6-rru-11-069] Similarly, there was no significant difference in all-cause mortality among these same groups (10.9, 10.1, and 10.3 deaths per 1,000 person-years, respectively).[@b6-rru-11-069] These findings are corroborated by the two largest prospective AS cohorts (Sunnybrook Health Sciences Center and Johns Hopkins University). Only 0.15% of patients in the Johns Hopkins series had died of prostate cancer at 15 years, and the cancer-specific survival rate of the Sunnybrook cohort was 98% at 10 years.[@b11-rru-11-069]

Despite the higher rate of disease progression in AS compared to intervention, there is no associated increased risk of death. However, when assessing barriers to conservative management of low-risk prostate cancer, it is also as important to examine patients' perception of risk as it is to examine the actual risk. Ultimately, it is the patient who decides how their disease will be managed. Indeed, it has been shown that there is significant discrepancy between perceived and actual risk associated with different modalities of prostate cancer treatment. One study showed that patients who had undergone RP estimated the mortality risk of AS at 50.9% compared to 17.8% for RP.[@b17-rru-11-069] These results demonstrate that failure in patient education remains one of the major barriers in the uptake of AS. The psychological impact of the conservative management of prostate cancer compared to active intervention represents an additional patient-related barrier to AS. It is reasonable to suspect that patients who are living with cancer will have increased anxiety compared to those who have undergone curative treatment. Indeed, there were early reports of increased levels of anxiety and depression in patients on watchful waiting,[@b18-rru-11-069] as well as of patients foregoing watchful waiting because of fear of possible consequences.[@b19-rru-11-069] However, two recent systematic reviews found that AS posed no greater risk of negative psychological impact than active treatment.[@b20-rru-11-069],[@b21-rru-11-069] Moreover, patient regret has been reported to be increased in patients undergoing RP and radiotherapy compared to watchful waiting (15.0%, 16.6%, and 8.2%, respectively).[@b22-rru-11-069] AS, however, has not been shown to be associated with increased regret compared to intervention.[@b23-rru-11-069] Overall, patients with prostate cancer considering AS should be advised that they would not be at increased risk of negative psychological impact.

There are certain clinical scenarios in which patients with low-risk prostate cancer may be appropriately managed with definitive therapy, such as RP. This includes patients with low-risk prostate cancer who suffer from severe lower-urinary-tract symptoms secondary to bladder-outlet obstruction. Additionally, some patients with low-risk prostate cancer on AS who are found to have a Prostate Imaging Reporting and Data System 5 lesion on multiparametric magnetic resonance imaging (mpMRI) may wish to proceed straight to RP before a confirmatory biopsy, given the high probability of clinically significant prostate cancer and the risks and discomfort of TRUS-bx. Though we strongly feel that pathological confirmation is a diagnostic gold standard and should be recommended in all instances prior to surgery, an RP in these patients may be considered. Finally, advances in robotic nerve-sparing RP have led to improved functional outcomes while maintaining oncological control in properly selected patients.[@b16-rru-11-069] However, despite the reduced morbidity of these techniques, surgery is never without risk. Regardless of the surgical technique and degree of nerve sparing, RP carries the risk of significant consequences, both functional (eg, incontinence, erectile dysfunction) and perioperative (eg, deep-vein thrombosis, pulmonary embolism, myocardial infection). Therefore, for the majority of patients with low-risk prostate cancer, the risk of surgery outweighs the potential benefit, even using novel nerve-sparing techniques.

In order for AS to be fully utilized, strategies and techniques must be developed to overcome barriers to its uptake. Regarding the risk of clinical progression, technologies are being studied in order to mitigate the increased risk in AS compared to curative treatment. One such tool is mpMRI, which is being increasingly used in the diagnosis and surveillance of patients with prostate cancer. mpMRI--TRUS fusion biopsy has been shown to offer increased detection of intermediate- and high-risk disease than standard 12-core TRUS-bx.[@b24-rru-11-069],[@b25-rru-11-069] Furthermore, novel biomarkers in addition to the traditional total PSA also show promise for improved patient assessment for AS candidacy. One example is the 4K Panel, a panel of four kallikreins: total PSA, free PSA, intact PSA, and human kallikrein 2. This panel has been shown to provide improved prediction of high-grade prostate cancer, and can also accurately reclassify patients already on AS.[@b26-rru-11-069],[@b27-rru-11-069] These new technologies can help ensure that patients with clinically significant prostate cancer are not missed while on AS. It is also worth noting that although widespread support for AS has generally been restricted to the low-risk prostate cancer patient population, there is emerging evidence to support use of AS for the management of favorable intermediate-risk prostate cancer. For example, a recent study found that patients on AS with intermediate-risk prostate cancer with Gleason 6 disease had similar metastasis-free survival compared to those with low-risk prostate cancer.[@b28-rru-11-069] Another recent review article laid out comprehensive guidelines for assessing intermediate-risk patients that should be deemed eligible for AS, including \<10%--20% Gleason 4 pattern on biopsy, low PSA density, and favorable molecular markers, if available.[@b29-rru-11-069]

Conclusion
==========

The proportion of patients undergoing RP at our institution who had low-risk prostate cancer decreased dramatically over the study period, likely due to an increase in the uptake of AS in this patient population. Further evaluation of the rates of AS and barriers to its uptake should be undertaken, in order further to reduce the unnecessary treatment of patients with low-risk prostate cancer.

The abstract of this study was presented at the 2018 CUA Annual Meeting.
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###### 

Radical prostatectomies performed at our institution 2005--2014 stratified by D'Amico risk classification

  Risk classification at biopsy                                            
  ------------------------------- ------------- ------------- ------------ ----------------------------------------------
  **2005**                        135 (54.0%)   105 (42.0%)   10 (4.0%)    250
  **2006**                        107 (43.5%)   121 (49.2%)   18 (7.3%)    246
  **2007**                        130 (53.3%)   97 (39.8%)    17 (7.0%)    244
  **2008**                        104 (43.2%)   128 (53.1%)   9 (3.7%)     241
  **2009**                        89 (35.3%)    150 (59.5%)   13 (5.2%)    252
  **2010**                        88 (38.1%)    131 (56.7%)   12 (5.2%)    231
  **2011**                        77 (29.5%)    165 (63.2%)   19 (7.3%)    261
  **2012**                        41 (15.6%)    195 (74.1%)   27 (10.3%)   263
  **2013**                        35 (15.1%)    172 (74.1%)   25 (10.8%)   232
  **2014**                        8 (8.9%)      68 (75.6%)    14 (15.6%)   90[a](#tfn1-rru-11-069){ref-type="table-fn"}

**Note:**

Data available for only part of 2014.

###### 

Radical prostatectomy pathological outcomes stratified by transrectal ultrasound--guided biopsy results

                                  Low risk at biopsy (total 814), n (%)   Intermediate risk at biopsy (total 1,332), n (%)   High risk at biopsy (total 164), n (%)
  ------------------------------- --------------------------------------- -------------------------------------------------- ----------------------------------------
                                                                                                                             
  **Postoperative grade group**                                                                                              
  1                               409 (50.2)                              98 (7.4)                                           7 (4.3)
  2                               374 (45.9)                              884 (66.4)                                         29 (17.7)
  3                               21 (2.6)                                281 (21.1)                                         47 (28.7)
  4                               6 (0.7)                                 30 (2.3)                                           18 (11.0)
  5                               4 (0.5)                                 39 (2.9)                                           63 (38.4)
                                                                                                                             
  **pT**                                                                                                                     
  pT2                             752 (92.4)                              953 (71.5)                                         61 (37.2)
  pT3a                            54 (6.6)                                264 (19.8)                                         52 (31.7)
  pT3b                            8 (1.0)                                 115 (8.6)                                          51 (31.1)
                                                                                                                             
  **Node status**                                                                                                            
  pN0                             543 (66.7)                              1,148 (86.2)                                       147 (89.6)
  pN1                             2 (0.2)                                 21 (1.6)                                           11 (6.7)
  pNx                             269 (33.0)                              163 (12.2)                                         6 (3.7)
                                                                                                                             
  **Lymphovascular invasion**                                                                                                
  Absent                          799 (98.2)                              1,242 (93.2)                                       137 (83.5)
  Present                         15 (1.8)                                90 (6.8)                                           27 (16.5)
